Sensitivity of BRCA-1-Related Breast Cancer to Neoadjuvant Chemotherapy: Practical Implications [2]

Breast Journal

Volumn 9, Issue 6, 2003, Pages 507-508

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; TRASTUZUMAB;

ADULT; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CONSERVATIVE TREATMENT; DRUG EFFECT; FEMALE; GENE MUTATION; HUMAN; LETTER; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ONCOGENE NEU; PATHOLOGY; TREATMENT OUTCOME; ULTRASOUND;

BRCA1 PROTEIN; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY;

EID: 0242552853     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2003.09624.x     Document Type: Letter

References (9)

1. Valero V. Primary chemotherapy with docetaxel for the management of breast cancer. Oncology 2002;16(suppl):35-43.
2. Narod SA, Brunet J-S, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 2000;356:1876-81.
3. King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-56.
4. Chappuis PO, Wong GJ, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608-10.
5. Amat S, Penault-Llorca F, Cure H, et al. Scarff-Bloom Richardson grading: a pleiotropic marker of chemosensitivity in invasive ductal carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002;20:791-96.
6. Colleoni M, Minchella I, Mazzarol G, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000;11:1057-59.
7. Wang J, Buchholtz TA, Middleton LP, et al. Assessment of histological features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 2002;94:3107-14.
8. Chang J, Elledge RM. Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 2001;69:101-13.
9. Kennedy RD, Quinn JE, Johnston PH, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360:1007-14.